Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Paul Dendale ,
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Prof Sigmund Silber MD, Prof Stephan Windecker MD, Pascal Vranckx MD, Prof Patrick W Serruys MD, on behalf of the RESOLUTE All Comers investigators doi:10.1016/S0140-6736(11)60395-4
In this trial, more than 1100 patients with angina pectoris were randomized to one of two different drug eluting stents (Resolute with zotarolimus versus Xience V with everolimus) and followed up for two years. The good news was a very low rate of very late stent thrombosis (0,3%). The number of patients needing an intervention for a stent problem (restenosis, stent thrombosis) was approximately 11% with no difference in the two groups. When looking at patient outcome, up to 20% of patients in both groups (no difference between groups) had a recurrent cardiac problem. The authors conclude : "The differences between stent-related and patient-related events can be regarded as more indicative of the patients’ underlying global disease, rather than related to the specific localised coronary obstruction treated with the study stents." The doubling of the number of patient problems as compared to stent problems shows that the extent of the underlying disease is at least as important for prognosis than the lesion in itself. According to Silber et al “optimisation of secondary prevention and overall medical management during long-term follow-up seems to be more important thanc the initial choice between advanced, new generation drug-eluting stents”. Hopefully, it will now be less difficult to convince the interventional cardiologists to refer their patients to cardiac rehabilitation